Table 3 Comparison of baseline TSH level, NLR, PLR and PNI between TD and non-TD subgroups
From: Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
| Â | TD subgroup | Non-TD subgroup | p |
|---|---|---|---|
(n = 39) | (n = 81) |  | |
Baseline | |||
 TSH level (M, IQR) (mlU/L) | 2.33 (1.84–4.19) | 1.58 (0.88–2.68) | 0.001 |
 NLR (M, IQR) | 4.33 (2.04–4.32) | 4.78 (2.25–4.78) | 0.451 |
 PLR (M, IQR) | 162.00 (125.26–244.00) | 160.7 (110.79–219.89) | 0.363 |
 PNI (M, IQR) | 48.1 (44.30–52.70) | 48.15 (43.18–52.25) | 0.893 |
Post-treatment | |||
 NLR (M, IQR) | 2.77 (2.40–4.80) | 3.02 (1.98–4.04) | 0.677 |
 PLR (M, IQR) | 159.44 (102.51–237.31) | 152.16 (112.98–208.02) | 0.923 |
 PNI (x ± s) | 48.53 ± 6.19 | 48.33 ± 4.97 | 0.849 |